SEC Form 4 · accession 0001179110-16-029261
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark J Gergen
Officer — SVP, Chief Operating Officer
Period of report
Sep 1, 2016
Accepted (ET)
Sep 2, 2016 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF1 | $9.97 | Sep 1, 2016 | A | 333,890 | A | Sep 1, 2017 | Sep 1, 2026 | Common Stock | 333,890 | 333,890 | D |
Explanation of responses
- F1This option vests one-fourth on such date and then 1/48 monthly thereafter.